Ferdinandos Skoulidis

11PUBLICATIONS
220CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 22, 2026
Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT).

|Jun 08, 2026
Cancer Chemoimmunotherapy: Time Will Tell.

|Nov 10, 2025
Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study.

Ferdinandos Skoulidis, Hossein Borghaei, Edward B Garon

|Aug 29, 2025
TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.

Leanne G Ahronian, Soumyadip Sahu, Minjie Zhang

|May 28, 2025
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer.

Ferdinandos Skoulidis, Bob T Li, Adrianus Johannes de Langen

|Feb 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

Pageof 2

Frequent Collaborators

5 joint publications

Marcelo V Negrao

5 joint publications

Don L Gibbons

5 joint publications

John V Heymach

4 joint publications

Giorgio Vittorio Scagliotti